Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and 2 surveys.
Naveen RParikshit SenZoltán GrigerJessica A DayMasataka KuwanaAlbert Selva-O'CallaghanElena NikiphorouSreoshy SahaAi Lyn TanSamuel Katsuyuki ShinjoNelly ZiadéTsvetelina V VelikovaMarcin MilchertKshitij JagtapIoannis ParodisAbraham Edgar Gracia-RamosLorenzo CavagnaMasataka KuwanaJohannes KnitzaYi Ming ChenAshima MakolVishwesh AgarwalAarat PatelJohn D PaulingChris WincupBhupen BarmanErick Adrian Zamora TehozolJorge Rojas SerranoIgnacio García-De La TorreIris Jazmin Colunga-PedrazaFrancisco Javier Merayo-ChalicoOkwara Celestine ChibuzoWanrachada KatchamartPhonpen Akawatcharangura GooRusska ShumnalievaLeonardo Santos HoffEl Lina KibbiHussein HalabiBinit VaidyaSyahrul Sazliyana ShaharirA T M Tanveer HasanDzifa DeyCarlos Enrique Toro GutiérrezCarlo Vinicio Caballero-UribeJames B LillekerBabur SalimTamer A GheitaTulika ChatterjeeOliver DistlerMiguel Ángel Saavedra-Salinasnull nullGabriela Arredondo Hector ChinoyVikas AgarwalRohit AggarwalLatika GuptaPublished in: Rheumatology (Oxford, England) (2023)
A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.